Life Sciences in 2026: Operating with Confidence in an Era of Regulation, Complexity and Resilience

The world’s largest pharmaceutical companies—incl. Eli Lilly, Merck & Co., Pfizer, AbbVie, and Johnson & Johnson—have fundamentally shifted their strategic focus. Rather than pursuing scale as the primary objective, these organizations are investing in more resilient, regionally anchored, and technologically advanced operating models.

Since 2023, this transformation has been characterized by expanded local manufacturing capabilities, dedicated production networks for advanced therapies, stronger vertical integration of critical supply chain components, and accelerated automation initiatives. Read our analysis and learn how the market leaders mentioned are tackling these and other challenges.

As the industry evolves, future operating models will need to strike a more effective balance between efficiency and security. Different scenarios emerge based on varying levels of regulatory pressure and portfolio complexity, but a clear direction is becoming apparent.

For a structured and valuable orientation, learn more about three powerful, interlocking forces which are shaping the current and future industry landscape: Regulation as a strategic driver, structural complexity and its costs, and resilience as an expectation – not as an option.

Our whitepaper complements this brief analysis with three scenarios showing how Life Science companies can navigate the tension between efficiency, innovation, and safety. Taking a solution-oriented approach, it outlines the strategic and operational direction you can adopt to successfully address market challenges.